Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Casma Therapeutics

How Pharma, Payers, & Providers are Leveraging Patient Self-Management Platforms

Rick Anderson, President of DarioHealth, explores digital therapeutics, how DarioHealth is utilizing AI and behavioral science to personalize each user’s health journey, and how this approach can help improve diversity...

Impetus Digital

- PMLiVE

Merck to donate Sudan Ebola virus vaccine to International AIDS Vaccine Initiative

Around 50,000 doses are expected to be provided for further clinical research use

- PMLiVE

How to elevate your communications testing with AI powered insights and analytics

Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers

Research Partnership

- PMLiVE

Merck’s Prevymis shows promise in phase 3 cytomegalovirus disease prevention trial

The drug demonstrated non-inferior efficacy compared to standard of care valganciclovir

- PMLiVE

Moderna’s Omicron BA.1 booster shows superior antibody response over Spikevax

Data indicates that the superior response is sustained for at least three months

- PMLiVE

Merck and Bill & Melinda Gates Institute sign licensing agreement for tuberculosis candidates

The non-profit will determine their potential for inclusion in new affordable treatment regimens

- PMLiVE

Moderna and Gavi update COVAX supply deal to include variant-specific COVID-19 vaccines

The agreement aims to ensure equitable access to low- and middle- income countries

- PMLiVE

Merck and Moderna to jointly develop personalised cancer vaccine in $250m deal

The vaccine is currently being evaluated as a treatment for high-risk melanoma patients

- PMLiVE

Merck to initiate phase 3 HIV-1 clinical programme with a lower dose of islatravir

A phase 2 study evaluating islatravir with Gilead’s lenacapavir will also resume with the lower dose

- PMLiVE

Moderna’s Omicron BA.1 targeting bivalent booster recommended by CHMP for use in EU

Results from a phase 2/3 trial demonstrated mRNA-1273.214 had superior neutralising antibody response against Omicron compared to the currently authorised booster

- PMLiVE

Moderna granted FDA authorisation for emergency use of BA.4/BA.5-targeting bivalent COVID-19 booster

The application was based on preclinical data and clinical trial data available from a phase 2/3 study evaluation of the company's BA.1 Omicron-targeting bivalent booster candidate

- PMLiVE

Moderna sues Pfizer/BioNTech over COVID-19 vaccine technology

The company believes two key features of its patented mRNA technology platform were copied

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links